{"id":"https://openalex.org/W3174691046","doi":"https://doi.org/10.2337/db21-647-p","title":"647-P: Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial","display_name":"647-P: Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial","publication_year":2021,"publication_date":"2021-06-01","ids":{"openalex":"https://openalex.org/W3174691046","doi":"https://doi.org/10.2337/db21-647-p","mag":"3174691046"},"language":"en","primary_location":{"id":"doi:10.2337/db21-647-p","doi":"https://doi.org/10.2337/db21-647-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db21-647-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073949429","display_name":"Matthew Capehorn","orcid":"https://orcid.org/0000-0002-8196-2505","observed_orcids":["https://orcid.org/0000-0002-8196-2505"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MATTHEW CAPEHORN","raw_affiliation_strings":["Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009303872","display_name":"Andrei\u2010Mircea Catarig","orcid":"https://orcid.org/0000-0002-7667-8315","observed_orcids":["https://orcid.org/0000-0002-7667-8315"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ANDREI-MIRCEA CATARIG","raw_affiliation_strings":["Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084475623","display_name":"Ofir Frenkel","orcid":"https://orcid.org/0009-0005-7928-744X","observed_orcids":["https://orcid.org/0009-0005-7928-744X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"OFIR FRENKEL","raw_affiliation_strings":["Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041014919","display_name":"Charlotte Hindsberger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"CHARLOTTE HINDSBERGER","raw_affiliation_strings":["Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088350286","display_name":"Michel Marre","orcid":"https://orcid.org/0000-0002-3071-1837","observed_orcids":["https://orcid.org/0000-0002-3071-1837"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MICHEL MARRE","raw_affiliation_strings":["Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058668146","display_name":"Hermione Clare Price","orcid":"https://orcid.org/0000-0003-3388-0975","observed_orcids":["https://orcid.org/0000-0003-3388-0975"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"HERMIONE PRICE","raw_affiliation_strings":["Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059098934","display_name":"Richard E. Pratley","orcid":"https://orcid.org/0000-0002-2912-1389","observed_orcids":["https://orcid.org/0000-0002-2912-1389"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"RICHARD E. PRATLEY","raw_affiliation_strings":["Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rotherham, United Kingdom, S\u00f8borg, Denmark, Neuilly-sur-Seine, France, Lyndhurst, United Kingdom, Orlando, FL","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.11063867,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"70","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9670000076293945},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.8769999742507935},{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":0.8119999766349792},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9639999866485596},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8460000157356262},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.7099999785423279},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9679999947547913},{"id":"https://openalex.org/keywords/body-weight","display_name":"body weight","score":0.8040000200271606},{"id":"https://openalex.org/keywords/systolic-blood-pressure","display_name":"systolic blood pressure","score":0.9909999966621399},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7310000061988831},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6949999928474426},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.8709999918937683},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.9980000257492065}],"concepts":[{"id":"https://openalex.org/C2909862629","wikidata":"https://www.wikidata.org/wiki/Q27261089","display_name":"Semaglutide","level":5,"score":0.9110361337661743},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.8795607686042786},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8331252932548523},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.7498616576194763},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.7209796905517578},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.650240421295166},{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.6391100287437439},{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.5921381115913391},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.5759222507476807},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5375691652297974},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5221155881881714},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.5010960102081299},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.500232458114624},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4560541808605194},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.3986627161502838},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.20158106088638306},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.17596468329429626},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.08758452534675598},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.06180572509765625}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db21-647-p","doi":"https://doi.org/10.2337/db21-647-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db21-647-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7223577711","https://openalex.org/W2996732450","https://openalex.org/W3046881359","https://openalex.org/W2989556657","https://openalex.org/W3095919402","https://openalex.org/W3091975544","https://openalex.org/W3035569335","https://openalex.org/W2948910559","https://openalex.org/W3003766971","https://openalex.org/W3167119233"],"abstract_inverted_index":{"Glucagon-like":[0],"peptide-1":[1],"receptor":[2],"agonist":[3],"(GLP-1RA)":[4],"and":[5,21,29,57,83,95,100,116,136,144,163,165,197],"sodium-glucose":[6],"cotransporter-2":[7],"inhibitor":[8],"(SGLT-2i)":[9],"combination":[10],"data":[11,71,85],"are":[12],"limited.":[13],"The":[14],"SUSTAIN":[15,44,69],"10":[16,45,70],"trial":[17],"analyzed":[18],"the":[19,24,178],"efficacy":[20,90],"safety":[22,101,157,201],"of":[23,43,149,183],"GLP-1RAs":[25,51],"semaglutide":[26,141],"1.0":[27,142],"mg":[28,32,143,147],"liraglutide":[30,145],"1.2":[31,146],"in":[33,52,58,133,159,173,194],"subjects":[34,53,160],"with":[35,49,140,191],"type":[36],"2":[37],"diabetes.":[38],"This":[39],"post":[40,66],"hoc":[41,67],"analysis":[42],"examined":[46],"clinical":[47],"outcomes":[48],"these":[50],"on":[54],"background":[55,117],"SGLT-2i":[56,75,112,150,175,187],"those":[59],"not":[60],"receiving":[61,161],"an":[62],"SGLT-2i.":[63],"In":[64],"this":[65],"analysis,":[68],"were":[72,86,122,138,154],"stratified":[73],"by":[74],"use":[76,151],"at":[77],"screening.":[78],"\u2018On-treatment":[79],"without":[80,199],"rescue":[81],"medication\u2019":[82],"\u2018on-treatment\u2019":[84],"used":[87],"to":[88,104,130,168,186],"assess":[89],"(HbA1c,":[91],"body":[92],"weight":[93],"[BW]":[94],"systolic":[96],"blood":[97],"pressure":[98],"[SBP])":[99],"(discontinuation":[102],"due":[103,167],"adverse":[105],"events":[106],"[AEs])":[107],"outcomes,":[108],"respectively.":[109],"Within":[110],"each":[111],"subgroup,":[113],"baseline":[114,129],"characteristics":[115],"medications":[118],"(metformin":[119],"and/or":[120],"sulfonylureas)":[121],"similar":[123],"between":[124],"treatment":[125,188],"arms.":[126],"Reductions":[127],"from":[128],"week":[131],"30":[132],"HbA1c,":[134,195],"BW":[135,196],"SBP":[137,198],"observed":[139],"regardless":[148],"(Figure).":[152],"There":[153],"no":[155],"unexpected":[156],"concerns":[158],"GLP-1RA":[162,185],"SGLT-2i,":[164],"discontinuations":[166],"AEs":[169],"remained":[170],"relatively":[171],"low":[172],"both":[174],"subgroups.In":[176],"conclusion,":[177],"results":[179],"suggest":[180],"that":[181],"addition":[182],"a":[184],"was":[189],"associated":[190],"further":[192],"reductions":[193],"additional":[200],"concerns.View":[202],"largeDownload":[203,205],"slideView":[204],"slide":[206],"DisclosureM.":[207],"Capehorn:":[208],"Advisory":[209],"Panel;":[210],"Self;":[211,220,224,235,241,247,252,262,267,280,287,294,299,304,319],"Boehringer":[212,225,306],"Ingelheim":[213,226,307],"Pharmaceuticals,":[214,227,296,311],"Inc.,":[215,228,331,335,341],"McDonalds,":[216],"Novo":[217,231,236,242,248,253,263,268,273,288,300,312,332],"Nordisk,":[218,232,301,333],"Consultant;":[219,261,286],"Lighterlife,":[221],"Research":[222,297],"Support;":[223,298],"Lilly":[229],"Diabetes,":[230],"Speaker\u2019s":[233,302],"Bureau;":[234,303],"Nordisk.":[237,243,289,313],"A.":[238],"Catarig:":[239],"Employee;":[240,246],"O.":[244],"Frenkel:":[245],"Nordisk":[249,254,264,269,274,346],"A/S,":[250,255,265,270],"Stock/Shareholder;":[251,266,271],"Thermo":[256],"Fisher":[257],"Scientific.":[258],"C.":[259],"Hindsberger:":[260],"Spouse/Partner;":[272],"A/S.":[275],"M.":[276],"Marre:":[277],"Board":[278],"Member;":[279],"Merck":[281,322],"Sharp":[282,323],"&":[283,324],"Dohme":[284,325],"Corp.,":[285,326],"H.":[290],"Price:":[291],"Other":[292,317],"Relationship;":[293,318],"Napp":[295,310],"AstraZeneca,":[305],"International":[308],"GmbH,":[309],"R.":[314],"E.":[315],"Pratley:":[316],"Hanmi":[320],"Pharmaceutical,":[321],"Metavention,":[327],"Monster":[328],"Energy":[329],"Company,":[330],"Pfizer":[334],"Poxel":[336],"SA,":[337],"Sanofi,":[338],"Scohia":[339],"Pharma":[340],"Sun":[342],"Pharmaceutical":[343],"Industries":[344],"Ltd.FundingNovo":[345],"A/S":[347]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-07-05T00:00:00"}